Unlike standard retail pharmacies, we stock pharmaceutical-grade BAC water specifically for patients, clinics, together with healthcare professionals

Post-hoc analysis of SYNERGY-NASH trial reveals key insights on #tirzepatide in #MASH patients MASH resolution linked to greater weight loss (-16% vs -7%) Fibrosis improvement associated with better glycemic control Liver fat normalization was key mediator of both outcomes Weight reduction + metabolic improvements = disease modification potential in MASH Scott Isaacs, MD, FACP, FACEs Post Post-hoc analysis of SYNERGY-NASH trial reveals key insights on #tirzepatide in #MASH patients MASH resolution linked to greater weight loss (-16% vs -7%) Fibrosis improvement associated with better glycemic control Liver fat normalization was key mediator of both outcomes Weight reduction + metabolic improvements = disease modification potential in MASH To view or add a comment, sign in More Relevant Posts Post-hoc analysis of SYNERGY-NASH trial showing how tirzepatide-driven weight loss and metabolic improvements are linked to MASH resolution and fibrosis improvement

Combination NRT (patch + gum or lozenge) works better than single products
Abruptly discontinuing the use of the medication may lead to weight gain, requiring continuous medical monitoring
your appetite dials down, your stomach empties more slowly, and your blood sugar stabilizes